Journal article 733 views 151 downloads
Epilepsy, antiepileptic drugs, and the risk of major cardiovascular events
,
Arron Lacey,
Beata Fonferko-Shadrach,
Daniel Harris,
Ashley Akbari ,
Ronan Lyons ,
Mark Rees,
Inder Sawhney,
Julian Halcox ,
Robert Powell,
Owen Pickrell
Epilepsia, Volume: 62, Issue: 7, Pages: 1604 - 1616
Swansea University Authors:
Fatemeh Torabi , Arron Lacey, Beata Fonferko-Shadrach, Ashley Akbari , Ronan Lyons , Mark Rees, Inder Sawhney, Julian Halcox , Robert Powell, Owen Pickrell
-
PDF | Version of Record
© 2021 The Authors. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License
Download (832.46KB)
DOI (Published version): 10.1111/epi.16930
Abstract
ObjectiveThis study was undertaken to determine whether epilepsy and antiepileptic drugs (including enzyme-inducing and non-enzyme-inducing drugs) are associated with major cardiovascular events using population-level, routinely collected data.MethodsUsing anonymized, routinely collected, health car...
| Published in: | Epilepsia |
|---|---|
| ISSN: | 0013-9580 1528-1167 |
| Published: |
Wiley
2021
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa56988 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract: |
ObjectiveThis study was undertaken to determine whether epilepsy and antiepileptic drugs (including enzyme-inducing and non-enzyme-inducing drugs) are associated with major cardiovascular events using population-level, routinely collected data.MethodsUsing anonymized, routinely collected, health care data in Wales, UK, we performed a retrospective matched cohort study (2003–2017) of adults with epilepsy prescribed an antiepileptic drug. Controls were matched with replacement on age, gender, deprivation quintile, and year of entry into the study. Participants were followed to the end of the study for the occurrence of a major cardiovascular event, and survival models were constructed to compare the time to a major cardiovascular event (cardiac arrest, myocardial infarction, stroke, ischemic heart disease, clinically significant arrhythmia, thromboembolism, onset of heart failure, or a cardiovascular death) for individuals in the case group versus the control group.ResultsThere were 10 241 cases (mean age = 49.6 years, 52.2% male, mean follow-up = 6.1 years) matched to 35 145 controls. A total of 3180 (31.1%) cases received enzyme-inducing antiepileptic drugs, and 7061 (68.9%) received non-enzyme-inducing antiepileptic drugs. Cases had an increased risk of experiencing a major cardiovascular event compared to controls (adjusted hazard ratio = 1.58, 95% confidence interval [CI] = 1.51–1.63, p < .001). There was no notable difference in major cardiovascular events between those treated with enzyme-inducing antiepileptic drugs and those treated with non-enzyme-inducing antiepileptic drugs (adjusted hazard ratio = .95, 95% CI = .86–1.05, p = .300).SignificanceIndividuals with epilepsy prescribed antiepileptic drugs are at an increased risk of major cardiovascular events compared with population controls. Being prescribed an enzyme-inducing antiepileptic drug is not associated with a greater risk of a major cardiovascular event compared to treatment with other antiepileptic drugs. Our data emphasize the importance of cardiovascular risk management in the clinical care of people with epilepsy. |
|---|---|
| Keywords: |
cardiovascular risk; enzyme-inducing antiepileptic drugs |
| College: |
Faculty of Medicine, Health and Life Sciences |
| Funders: |
This work was supported by Health Data Research UK, which receives its funding from HDR UK (HDR-9006) funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation, and Wellcome Trust. This work was supported by staff funded as part of the Brain Repair and Intracranial Neurotherapeutics (BRAIN) Unit Infrastructure Award (grant UA05). The BRAIN Unit is funded by the Welsh Government through Health and Care Research Wales. This study makes use of anonymized data held in the SAIL Databank. |
| Issue: |
7 |
| Start Page: |
1604 |
| End Page: |
1616 |